Hepatocellular carcinoma
Conditions
Interventions
Group 1 :
Sponsors
Mengchao Hepatobiliary Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 years old = 10 mm or malignant lymph node short diameter >= 15 mm, see Annex 5/6 for mRECIST version 1.1); 3. Patients with unresectable hepatocellular carcinoma who have not received systemic therapy before or have progressed/intolerable after first-line systemic therapy; 4. CNLC stage is IIb-IIIb; 5. The Child-Pugh classification of liver function is grade A or grade B (5-7 points); 6. ECOGPS score 0-1 points; 7. Expected survival period >= 12 weeks; 8. If the patient suffers from active hepatitis B virus (HBV) infection: if HBV-DNA 2000, antiviral treatment should be given for one week before starting treatment; 9. Subjects voluntarily join this study, have good compliance, and cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with contraindications to immunotherapy, including but not limited to the following: patients after transplantation, patients with severe autoimmune diseases, patients with organ failure, patients with adverse reactions of grade 4 or above in the past using immunotherapy, and patients with uncontrollable infectious diseases patients, etc.; 3. Immunosuppressants or systemic hormone therapy were used within 14 days before enrollment to achieve the purpose of immunosuppression (dose > 10 mg/day prednisone or other equivalent curative hormones); 4. Patients who have been confirmed to be allergic to camrelizumab injection, apatinib mesylate tablets and their excipients or to other monoclonal antibodies; 5. Patients with impaired consciousness or unable to cooperate with treatment, combined with patients with mental illness; 6. Patients who have participated in other clinical trials in the past three months; 7. Severe liver, kidney, heart, lung, brain and other major organ failure; 8. According to the investigator's judgment, patients with other concomitant diseases that seriously endanger the safety of patients or affect the completion of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Disease control rate;overall survival;Safety; | — |
Countries
China
Contacts
Public ContactYongyi Zeng
Mengchao Hepatobiliary Hospital of Fujian Medical University
Outcome results
None listed